Episode

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

Podcast: BioSpace
Published: Jul 15, 2026
Duration seconds: 1282
Processing state: not_requested
Canonical source: https://api.riverside.com/hosting-analytics/media/874db7e54d926518b357f18c70ab304281df29be048bb454375512d425cda6ef/eyJlcGlzb2RlSWQiOiI3Y2U0YWM1Yi1hYzQyLTRjYzYtODY4Mi1kYTFhNDI3OWRhZWYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1Njg1OGYyY2UxMTM1ZGUxMDQ2YmI4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTE0X18yMC01My0zLm1wMyJ9.mp3
Audio: https://api.riverside.com/hosting-analytics/media/874db7e54d926518b357f18c70ab304281df29be048bb454375512d425cda6ef/eyJlcGlzb2RlSWQiOiI3Y2U0YWM1Yi1hYzQyLTRjYzYtODY4Mi1kYTFhNDI3OWRhZWYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1Njg1OGYyY2UxMTM1ZGUxMDQ2YmI4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTE0X18yMC01My0zLm1wMyJ9.mp3
JSON: /v1/public/podcasts/biospace-6696251/episodes/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup
Markdown: /podcast/biospace-6696251/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup.md

Actions

POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/biospace-6696251/biogen-validates-anti-tau-approach-at-aaic-psychedelics-full-speed-ahead-attr-cm-shakeup.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.